<DOC>
	<DOC>NCT00539630</DOC>
	<brief_summary>To describe the clinical response rate in two groups (Docetaxel plus cisplatin plus 5-FU, versus Cisplatin plus 5-FU) after 3 cycle of neoadjuvant chemotherapy.</brief_summary>
	<brief_title>TAX + Cisplatin + 5 F/U vs Cisplatin + 5 F/U in SCCHN</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Squamous Cell</mesh_term>
	<criteria>Histologically or cytologically proven squamous cell carcinoma of the head and neck with locally advanced inoperable disease. Primary tumor sites eligible: oral cavity, oropharynx, hypopharynx , larynx or nasopharynx. Patients are required to have at least one (bior unidimensionally) measurable lesion. WHO performance status 0 or 1. Adequate bone marrow, hepatic and renal functions. Pregnant and lactating women Previous chemotherapy Previous radiotherapy for H&amp;N Previous surgery for H&amp;N The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2007</verification_date>
</DOC>